Organogenesis Holdings Inc. (ORGO) stock
Close on Nov 12, 2026Market cap $124.17MP/E –Yield –
Organogenesis Holdings Inc. saw revenue fall 24.3% to $352.05M over the twelve months to Sep 30, 2026. Free cash flow was -$64.00K. At the latest close the market valued the company at $124.17M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $124.17M
- P/E ratio
- –
- Price to sales
- 0.35
- Price to book
- 1.04
- Dividend yield
- –
- Free cash flow yield
- -0.05%
Fundamentals
- Revenue
- $352.05M
- Net income
- -$135.35M
- EPS, diluted
- -$1.21
- Free cash flow
- -$64.00K
- Book value per share
- $0.93
- Diluted shares
- 129M
Trading
- Next earnings
- Feb 25, 2027 (estimated, during market hours)
- Previous close
- $1.05
- Open
- $1.05
- Day's range
- $0.95 – $1.05
- Volume
- 1,220,803
- Average volume (20 days)
- 1,218,365
- Index membership
- Russell 2000, Russell 3000 (since Feb 2021)
- Beta (5 years)
- 1.17
- 52-week range
- $0.73 – $6.56
- RSI (14 days)
- 46.1
- Volatility (1 year)
- 65.9%
- Relative volume
- 1.43×
- WACC
- 10.7%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ORGO | S&P 500 | Difference | ORGO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -21.5% | -2.7% | −18.8 pts | ||
| 3 months | -46.7% | -1.7% | −44.9 pts | ||
| Year to date | -81.4% | +11.9% | −93.3 pts | ||
| 1 year | -85.1% | +12.0% | −97.1 pts | ||
| 3 years | -55.9% | +78.2% | −134.1 pts | -23.9% | +21.2% |
| 5 years | -91.4% | +73.2% | −164.6 pts | -38.7% | +11.6% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Organogenesis filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Organogenesis
Pharmaceutical Preparations
Organogenesis Holdings Inc. develops, manufactures, and sells regenerative medicine solutions. The company operates across two primary commercial segments: Advanced Wound Care and Surgical & Sports Medicine. Its advanced wound care offerings include products such as Apligraf, Dermagraft, PuraPly, CYGNUS, VIA Matrix, Affinity, Novachor, NuShield, and SimpliMax, which treat acute and chronic wounds, including diabetic foot ulcers and venous leg ulcers. In the surgical and sports medicine segment, the company supplies products like PuraForce, NuShield, Cygnus Matrix, and PuraPly for soft tissue repair, tendon and ligament injuries, and open surgical wounds. Its customer base includes hospitals, outpatient wound care centers, government facilities, ambulatory surgery centers, and physician offices.
Company profile, executives and historyOrganogenesis stock: common questions
What is Organogenesis's stock price?
ORGO closed at $0.96 on Nov 12, 2026, down 8.10% on the day. Over the past 52 weeks it traded between $0.73 and $6.56.
What is Organogenesis's market cap?
Organogenesis was worth $124.17M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ORGO's P/E ratio?
Organogenesis lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.21), so it has no meaningful P/E ratio.
How much revenue does Organogenesis make?
Organogenesis reported revenue of $352.05M for the twelve months to Sep 30, 2026, down 24.3% from a year earlier.
Does Organogenesis pay a dividend?
No. Organogenesis has not paid a cash dividend over the last twelve months.
When does Organogenesis report earnings next?
Organogenesis is expected to report Q4 FY2026 results on Feb 25, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ORGO stock performed over the past year?
Including dividends, ORGO returned -85.1% over the past year, against +12.0% for the S&P 500.
Who are Organogenesis's competitors?
Companies most similar to Organogenesis by business, industry and size include VCEL, CRMD, XERS, KMDA, EOLS.
See a number that looks wrong?